Kalliope
Senior Member (Voting Rights)
The Lancet New NICE guideline on chronic fatigue syndrome: more ideology than science?
Signe A. Flottorp, Kjetil Brurberg, Per Fink, Hans Knoop, Vegard B B Wyller
Article is paywalled other than this text (references removed):
The National Institute for Health and Care Excellence (NICE) in the UK published a new chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) guideline in October, 2021.
The previous NICE 2007 guideline recommended cognitive behavioural therapy (CBT) and graded exercise therapy (GET) for people with mild or moderate CFS/ME based on evidence from randomised trials.
Since then, more randomised trials and systematic reviews have provided additional evidence supporting these recommendations.
No new or more effective interventions have been identified. Although we applaud guideline efforts, it is remarkable that recommendations in the 2021 NICE guideline differ substantially from the previous one, and do not include CBT and GET as means to treat CFS/ME. The new guideline presents strengthened evidence, but a major shift in interpretation. How could this happen?
Signe A. Flottorp, Kjetil Brurberg, Per Fink, Hans Knoop, Vegard B B Wyller
Article is paywalled other than this text (references removed):
The National Institute for Health and Care Excellence (NICE) in the UK published a new chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) guideline in October, 2021.
The previous NICE 2007 guideline recommended cognitive behavioural therapy (CBT) and graded exercise therapy (GET) for people with mild or moderate CFS/ME based on evidence from randomised trials.
Since then, more randomised trials and systematic reviews have provided additional evidence supporting these recommendations.
No new or more effective interventions have been identified. Although we applaud guideline efforts, it is remarkable that recommendations in the 2021 NICE guideline differ substantially from the previous one, and do not include CBT and GET as means to treat CFS/ME. The new guideline presents strengthened evidence, but a major shift in interpretation. How could this happen?